Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,180,820.35. The trade was a 6.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00.
• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Stock Performance

PCVX stock opened at $82.47 on Friday. The stock has a market capitalization of $10.28 billion, a P/E ratio of -17.93 and a beta of 0.98. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06. The company has a 50 day moving average price of $85.77 and a two-hundred day moving average price of $94.57.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PCVX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and set a $14.00 price objective on shares of Vaxcyte in a research note on Tuesday, February 11th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and an average price target of $127.71.

Institutional Trading of Vaxcyte

Several hedge funds and other institutional investors have recently bought and sold shares of PCVX. Janus Henderson Group PLC grew its stake in Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after acquiring an additional 2,052,989 shares during the period. Capital Research Global Investors grew its stake in Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company’s stock worth $508,393,000 after acquiring an additional 1,312,302 shares during the period. Norges Bank purchased a new stake in Vaxcyte in the 4th quarter worth approximately $90,069,000. Vanguard Group Inc. grew its stake in Vaxcyte by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock worth $979,184,000 after acquiring an additional 521,204 shares during the period. Finally, Paradigm Biocapital Advisors LP grew its stake in Vaxcyte by 57.3% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company’s stock worth $116,469,000 after acquiring an additional 518,255 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.